Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in California: - Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- City of Hope Corona — Corona, California
- UC Irvine Health Cancer Center-Newport — Costa Mesa, California
- Kaiser Permanente Downey Medical Center — Downey, California
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in California: - Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Contra Costa Regional Medical Center — Martinez, California
- Providence Queen of The Valley — Napa, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in California: - AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in California: - Research Site — Clovis, California
- Research Site — Los Alamitos, California
- Research Site — San Diego, California
- Research Site — Santa Monica, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in California: - Kaiser Permanente Southern California — Irvine, California
- University of California San Diego (Ucsd) Moores Cancer Center — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- UCLA Department of Medicine Hematologyoncology — Los Angeles, California
- Kaiser Permanente Oakland Medical Center — Oakland, California
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in California: - Alta Bates Summit Medical Center ( Site 0004) — Berkeley, California
- Moores Cancer Center ( Site 0003) — La Jolla, California
- Care Access - South Pasadena ( Site 0070) — Pasadena, California
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in California: - Ucsf Fresno — Fresno, California
- Kaiser Permanente Southern California — Irvine, California
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in California: - City of Hope (Adults and Pediatrics) — Duarte, California
- University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
- Loma Linda University Medical Center (Adults only) — Loma Linda, California
- Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics) — Los Angeles, California
- UCLA Medical Center (Adults and Pediatrics) — Los Angeles, California
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in California: - City of Hope National Medical Center — Duarte, California
- University of California, Irvine — Irvine, California
- University of California San Francisco — San Francisco, California
Phase 3 Recruiting Industry
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemot…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06051409
Sites in California: - Ascentage Investigative Site #1062 — Duarte, California
- Ascentage Investigative Site #1134 — Los Angeles, California
- Ascentage Investigative Site #1059 — Los Angeles, California
Phase 3 Recruiting Industry
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Saf…
Sponsor: Acrotech Biopharma Inc.
NCT ID: NCT06072131
Sites in California: - University of California, San Francisco Fresno — Clovis, California
- University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600 — Santa Monica, California
Phase 3 Recruiting Academic/Other
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New…
Sponsor: University College, London
NCT ID: NCT04685616
Sites in California: - Stanford University - (Stanford Cancer Institute) — Stanford, California
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in California: - City of Hope at Irvine Lennar — Irvine, California
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in California: - Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
- Children's Hospital of Orange County — Orange, California
Phase 2 Recruiting NIH
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06649812
Sites in California: - Cedars-Sinai Medical Center — Los Angeles, California
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope Seacliff — Huntington Beach, California
- City of Hope Antelope Valley — Lancaster, California
- City of Hope at Long Beach Elm — Long Beach, California
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in California: - Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) — Burbank, California
- City of Hope Comprehensive Cancer Center ( Site 0191) — Duarte, California
- Bass Medical Group ( Site 0123) — Walnut Creek, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…
Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in California: - University of California-Irvine Medical Center — Irvine, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles (UCLA) Medical Center — Los Angeles, California
- Scripps Clinic — San Diego, California
Phase 2 Recruiting Industry
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…
Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in California: - UC San Diego Health — La Jolla, California
- Stanford University — Stanford, California
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in California: - City of Hope — Duarte, California
- Providence St. John's Health Center — Santa Monica, California
- UCLA Department of Medicine - Hematology/Oncology — Santa Monica, California
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in California: - Research Site — Duarte, California
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in California: - University of California Irvine Medical Center — Orange, California
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
Phase 2 Recruiting Industry
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in California: - City of Hope National Medical Center — Duarte, California
- City of Hope National Medical Center — Irvine, California
- Palo Alto Medical Foundation Research Institute (PAMFRI) — Palo Alto, California
- Stanford Cancer Center — Palo Alto, California